V Ricotti
V Ricotti
Verified email at
Cited by
Cited by
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
T Voit, H Topaloglu, V Straub, F Muntoni, N Deconinck, G Campion, ...
The Lancet Neurology 13 (10), 987-996, 2014
Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations
V Ricotti, WPL Mandy, M Scoto, M Pane, N Deconinck, S Messina, ...
Developmental Medicine & Child Neurology 58 (1), 77-84, 2016
Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy
V Ricotti, DA Ridout, E Scott, R Quinlivan, SA Robb, AY Manzur, ...
Journal of Neurology, Neurosurgery & Psychiatry 84 (6), 698-705, 2013
Development of the P erformance of the U pper L imb module for D uchenne muscular dystrophy
A Mayhew, ES Mazzone, M Eagle, T Duong, M Ash, V Decostre, ...
Developmental Medicine & Child Neurology 55 (11), 1038-1045, 2013
Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation
M Pane, ME Lombardo, P Alfieri, A D'Amico, F Bianco, G Vasco, G Piccini, ...
The Journal of pediatrics 161 (4), 705-709. e1, 2012
The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
V Ricotti, DA Ridout, M Pane, M Main, A Mayhew, E Mercuri, AY Manzur, ...
Journal of Neurology, Neurosurgery & Psychiatry 87 (2), 149-155, 2016
Further delineation of Pitt–Hopkins syndrome: phenotypic and genotypic description of 16 novel patients
C Zweier, H Sticht, EK Bijlsma, J Clayton-Smith, SE Boonen, A Fryer, ...
Journal of medical genetics 45 (11), 738-744, 2008
Early neurodevelopmental assessment in Duchenne muscular dystrophy
M Pane, R Scalise, A Berardinelli, G D’Angelo, V Ricotti, P Alfieri, I Moroni, ...
Neuromuscular Disorders 23 (6), 451-455, 2013
A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy
ES Mazzone, G Vasco, C Palermo, F Bianco, C Galluccio, V Ricotti, ...
Developmental Medicine & Child Neurology 54 (10), 879-885, 2012
Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping
K Anthony, V Arechavala-Gomeza, V Ricotti, S Torelli, L Feng, N Janghra, ...
JAMA neurology 71 (1), 32-40, 2014
Severe childhood encephalopathy with dyskinesia and prolonged cognitive disturbances: evidence for anti‐N‐methyl‐d‐aspartate receptor encephalitis
C Poloni, CM Korff, V Ricotti, MD King, ER Perez, C MAYOR‐DUBOIS, ...
Developmental Medicine & Child Neurology 52 (5), e78-e82, 2010
Duchenne muscular dystrophy and epilepsy
M Pane, S Messina, C Bruno, A D’amico, M Villanova, B Brancalion, ...
Neuromuscular Disorders 23 (4), 313-315, 2013
Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single-and multiple-dose administration to pediatric patients with …
V Ricotti, S Spinty, H Roper, I Hughes, B Tejura, N Robinson, G Layton, ...
PloS one 11 (4), e0152840, 2016
Upper limb evaluation in Duchenne muscular dystrophy: fat-water quantification by MRI, muscle force and function define endpoints for clinical trials
V Ricotti, MRB Evans, CDJ Sinclair, JW Butler, DA Ridout, JY Hogrel, ...
PLoS One 11 (9), e0162542, 2016
Use of complementary and alternative medicine in epilepsy
V Ricotti, N Delanty
Current Neurology and Neuroscience Reports 6 (4), 347-353, 2006
Revised North Star Ambulatory Assessment for young boys with Duchenne muscular dystrophy
E Mercuri, G Coratti, S Messina, V Ricotti, G Baranello, A D’Amico, ...
PLoS One 11 (8), e0160195, 2016
Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts
V Cazzella, J Martone, C Pinnarò, T Santini, SS Twayana, O Sthandier, ...
Molecular Therapy 20 (11), 2134-2142, 2012
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53
C Brogna, G Coratti, M Pane, V Ricotti, S Messina, A D’Amico, C Bruno, ...
PLoS One 14 (6), e0218683, 2019
Ocular and neurodevelopmental features of Duchenne muscular dystrophy: a signature of dystrophin function in the central nervous system
V Ricotti, H Jägle, M Theodorou, AT Moore, F Muntoni, DA Thompson
European Journal of Human Genetics 24 (4), 562-568, 2016
Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: a prospective multicentre study
V Ricotti, V Selby, D Ridout, J Domingos, V Decostre, A Mayhew, M Eagle, ...
Neuromuscular Disorders 29 (4), 261-268, 2019
The system can't perform the operation now. Try again later.
Articles 1–20